Severe scalp ulcerations and granulomata during treatment with amivantamab by Jingjia J Zhou, Lanyi N Chen, Thomas Lehan, Benjamin Herzberg, Brian S Henick, Michael Pitman, Stephanie Gallitano, Catherine A Shu

Subjects: “…Amivantamab…”
Get full text

Amivantamab, the first epidermal growth factor receptor and mesenchymal–epithelial transition factor inhibitor, associated with penile and inguinal ulcers and paronychia by Karina J. Cancel-Artau, MD, Angélica C. Marrero-Pérez, MD, Eduardo A. Michelén-Gómez, MD, Xavier Sánchez-Flores, MD

Subjects: “…amivantamab…”
Get full text

Bioanalytical method development and validation for quantification of amivantamab in rat plasma by LC-MS/MS by Pridhvi Krishna Gaddey, Raja Sundararajan

Subjects: “…Amivantamab…”
Get full text

Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center’s Experience by Jingjing WANG, Yujia CHI, Hanxiao CHEN, Bo JIA, Xiaoyu ZHAI, Menglei MA, Jianjie LI, Minglei ZHUO

Subjects: Get full text

Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review by Alexander S Watson, Tejas Patil, Erin L Schenk, D Ross Camidge

Subjects: Get full text

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy by Vishal Shah, Andrea McNatty, Lacey Simpson, Henry Ofori, Farah Raheem

Subjects: “…amivantamab-vmjw…”
Get full text

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer by Jing Zhang, Wenjie Li

Subjects: “…Amivantamab…”
Get full text

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations by Zhang SS, Zhu VW

Subjects: Get full text

EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis by Ao Liu, Xiaoming Wang, Lian Wang, Han Zhuang, Liubo Xiong, Xiao Gan, Qian Wang, Guanyu Tao

Subjects: Get full text

Cost-effectiveness analysis of amivantamab plus chemotherapy versus chemotherapy alone in NSCLC with EGFR Exon 20 insertions by Ping Yue, Ping Yue, Mengwei Zhang, Mengwei Zhang, Yuanying Feng, Yuanying Feng, Yuan Gao, Yuan Gao, Chao Sun, Peng Chen, Peng Chen

Subjects: “…amivantamab…”
Get full text

Targeting EGFR Exon 20 Insertion-mutated Cancers – New Perspectives in Head and Neck Cancers – Lessons to Learn from Non-small Cell Carcinoma (NSCLC) by Camil Ciprian MIRESTEAN, Roxana Irina IANCU, Dragos Teodor IANCU

Subjects: Get full text

Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: A case series by Mariya N. George, BSA, Riyad N.H. Seervai, MD, PhD, Susan Y. Chon, MD

Subjects: Get full text

Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions by Kinsley Wang, Robert Hsu

Subjects: Get full text

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer by Brazel D, Nagasaka M

Subjects: “…amivantamab…”
Get full text

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease by Giulio Metro, Andrea De Giglio, Biagio Ricciuti, Marco Siringo, Daniele Marinelli, Alain Gelibter, Federica Pecci, Rossana Berardi, Luca Cantini, Alessandro Di Federico, Elisa Andrini, Mirta Mosca, Giuseppe Lamberti, Marta Brambilla, Giannis Mountzios

Subjects: “…amivantamab…”
Get full text

The development of amivantamab for the treatment of non-small cell lung cancer by Danielle Brazel, Misako Nagasaka

Subjects: “…Amivantamab…”
Get full text